Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
13.94
+0.92 (7.07%)
At close: Aug 13, 2025, 4:00 PM
13.86
-0.08 (-0.57%)
Pre-market: Aug 14, 2025, 8:47 AM EDT
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$429,605
Profits / Employee
-$257,605
Market Cap
1.05B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZYME News
- 3 days ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire
- 5 days ago - Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 17 days ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - GlobeNewsWire
- 4 weeks ago - Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewsWire
- 2 months ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 2 months ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire
- 2 months ago - Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewsWire